AHOD1331; A Randomized Phase III Study of Brentuximab Vedotin (SGN-35 IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Brief description of study
If you are the parent or guardian of a child/adolescent diagnosed with hodgkin lymphoma, your child may qualify to participate in a clinical trial investigating brentuximab vedotin and combination chemotherapy. The main goals of this study are to evaluate brentuximab & combination chemotherapy to see how well they work, compared to standard chemo alone, to better understand the biology of Hodgkin lymphoma in order to better predict which subjects have the highest risk of the disease coming back.
Clinical Study Identifier: s15-00950
ClinicalTrials.gov Identifier: NCTs15-00950
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
